BioTTT001

AXP000046.1 · Oncolytic virus

Platform
adenovirus (Ad5, triple-deleted: E1ACR2, E1B19K, E3gp19K)
Originator
Capital Medical University
Sponsor
Beijing Bio-Targeting Therapeutics Technology

Names

NameTypeSource
BioTTT001preferred name, codecurator, ncit
Ad-TD-nsIL12codectgov
Ad5-TD-nsIL-12synonymncit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 (Ad-TD)
Replication
conditionally replicating
Modifications
triple deletion: E1A CR2, E1B-19K and E3gp19K
Transgenes
IL12A, IL12B (non-secreting)
Route
intratumoral, intraperitoneal, intra arterial
Source
evidence

Cross-references

NCI Thesaurus
C205444

Approvals

No regulatory approval recorded.

Clinical trials (10)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07472790A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade GliomaNot yet recruitingPhase 12026-07-312028-04-3015High-grade Glioma
NCT06283134A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal CancerNot yet recruitingPhase 12026-032027-12-0160Colorectal Cancer Metastatic
NCT07264569Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001RecruitingPhase 1/22025-06-252027-12-3042Meningeal Metastasis
NCT07150767A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast CancerWithdrawnPhase 12025-03-262027-03-260Locally Advanced Breast Cancer (LABC)
NCT07126990Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade GliomaEnrolling by invitationPhase 1/22025-02-122028-08-3040Glioma
NCT06763965Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.Enrolling by invitationPhase 1/22024-11-262027-07-3130Recurrent High-grade Glioma
NCT06215846A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid TumorsEnrolling by invitationPhase 12024-05-072026-05-3012Solid Tumor
NCT06283121A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric CancerNot yet recruitingPhase 22024-04-022027-11-3030Gastric Cancer, Metastatic
NCT05717712Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine GliomaRecruitingPhase 12023-01-042025-01-0418Adverse Drug Event; Diffuse Intrinsic Pontine Glioma; Oncolytic Virus
NCT05717699Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine GliomaRecruitingPhase 12023-01-042025-01-0418Adverse Drug Event; Diffuse Intrinsic Pontine Glioma; Oncolytic Virus

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40721414The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials.Nature communications2025name in title: Ad-TD-nsIL12
PMID 39114662Treatment of intracranial inflammatory myofibroblastic tumor with PD-L1 inhibitor and novel oncolytic adenovirus Ad-TD-nsIL12: a case report and literature review.Frontiers in immunology2024name in title: Ad-TD-nsIL12
PMID 39516192Non-secreting IL12 expressing oncolytic adenovirus Ad-TD-nsIL12 in recurrent high-grade glioma: a phase I trial.Nature communications2024name in title: Ad-TD-nsIL12
PMID 33182528A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma.Cells2020cited by trial NCT05717712
PMID 29123084Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent.Nature communications2017cited by trial NCT05717712
PMID 19223865Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters.Molecular therapy : the journal of the American Society of Gene Therapy2009cited by trial NCT05717712

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41705010A Decade of Oncolytic Virotherapy in Pediatric Cancers: A Systematic Review of Safety, Immune Awakening, and Emerging Efficacy.Cureus2026name in abstract: Ad-TD-nsIL12
PMID 41741902Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors.Journal of neuro-oncology2026name in abstract: Ad-TD-nsIL12
PMID 38806994A viral attack on brain tumors: the potential of oncolytic virus therapy.Journal of neurovirology2024name in abstract: Ad-TD-nsIL12
PMID 37749907Oncolytic virotherapies for pediatric tumors.Expert opinion on biological therapy2023name in abstract: Ad-TD-nsIL12

Notes

Also written Ad-TD-nsIL12 / Ad5-TD-nsIL-12. The academic trials run by Capital Medical University (NCT05717712, NCT05717699) and the company trials of BioTTT001 appear to be the same construct; merged here on the strength of the NCIt synonym Ad5-TD-nsIL-12. Worth a curator check.

How to cite

BioTTT001 (AXP000046.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000046.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.